COYA 302, an injection therapy in development for the treatment of ALS, has been awarded fast track status by the U.S. Food and Drug Administration. The therapy aims to slow ALS progression by ...

Darin Nakakihara doesn’t remember much from the day that changed his life. He left the doctor’s office and walked to his car. In the driver’s seat, he looked up the disease he was just diagnosed with, ...

Fast-track status is intended to speed the development and review of treatments for serious conditions with unmet medical needs. It will allow Spinogenix to have more frequent interactions with the ...

Patients with amyotrophic lateral sclerosis (ALS), or Lou Gehrig's disease, live an average of only three years after ...

- AMX0114 is an Amylyx-developed antisense oligonucleotide designed to target calpain-2, a key contributor to the axonal degeneration pathway in ALS - Phase 1 LUMINA trial of AMX0114 underway; early ...

Please provide your email address to receive an email when new articles are posted on . AMX0114 was developed to target calpain-2, a driver of axonal neurodegeneration. A pending clinical trial will ...

AMX0114 is an investigational antisense oligonucleotide targeting calpain-2, a calcium-activated protease believed to play a role in ALS disease progression. The Food and Drug Administration (FDA) has ...

Long-term exposure to common air pollutants is associated with a higher risk of developing motor neuron disease (MND), as well as faster functional decline and poorer survival after diagnosis — even ...

Eric Dane, widely known for his character of Dr. Mark Sloan in popular TV drama Grey's Anatomy, has died at 53. The actor, in April 2025, shared that he was diagnosed with amyotrophic lateral ...

Darin Nakakihara doesn’t remember much from the day changed his life. He left the doctor’s office and walked to his car. In the driver’s seat, he looked up the disease he was just diagnosed with, and ...